Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.17
-0.0600-4.88%
Volume:57.90K
Turnover:69.05K
Market Cap:18.51M
PE:-1.62
High:1.26
Open:1.20
Low:1.17
Close:1.23
52wk High:2.35
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:1.69
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7218
EPS(LYR):-0.7811
ROE:-87.92%
ROA:-23.70%
PB:2.67
PE(LYR):-1.50

Loading ...

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

GlobeNewswire
·
Jul 07

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib Drp® Companion Diagnostic

Reuters
·
Jul 06

Allarity Therapeutics - Has Patent Protection for Stenoparib Drp in Europe and Australia into 2039

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics - Granted Patent Term Extends into April 2042

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

GlobeNewswire
·
Jun 30

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress

Reuters
·
Jun 22

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

TIPRANKS
·
Jun 18

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO Gynaecological Cancers Congress 2026

Reuters
·
Jun 18

Allarity Therapeutics sets CEO consulting pay at SEK 6 million plus USD 163,043 for 2026 under amended services agreement

Reuters
·
Jun 03

Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

THOMSON REUTERS
·
May 16

Allarity Therapeutics Q1 FY26 net loss narrows to $2.75 million

Reuters
·
May 16

Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement

Reuters
·
May 12

Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026

Reuters
·
May 08

Allarity Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
May 07

Allarity says Phase 3 stenoparib manufacturing campaign stays on track for Q3 2026 completion

Reuters
·
May 05

Allarity receives notice of allowance from USPTO

TIPRANKS
·
Apr 27

Allarity Therapeutics Inc - Patent Expected to Be Formally Granted Within Three Months, Subject to Standard Administrative Procedures

THOMSON REUTERS
·
Apr 27

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

GlobeNewswire
·
Apr 27

Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial

Reuters
·
Apr 21